Corbus Pharmaceuticals (NASDAQ: CRBP) insider transactions
In the twelve months to 10 November 2026, executives and directors of Corbus Pharmaceuticals reported 14 open-market sales of 526,483 shares ($2.7m) and 3 open-market purchases of 16,100 shares ($126,243), by 11 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 29 October 2026 | Cormorant Asset Management, LP | — | Open-market sale | −425,000 | $4.10 | 1,919,971 | Form 4 |
| 14 September 2026 | Ben Yong | Director | Open-market sale | −2,000 | $7.84 | 9,383 | Form 4 |
| 16 August 2026 | Nicacio Leonardo Viana | Chief Medical Officer | Grant or award | +58,333 | — | 58,333 | Form 4 |
| 11 August 2026 | Saxena Nishant C | Chief Business Officer | Open-market purchase | +2,600 | $9.63 | 77,900 | Form 4 |
| 7 August 2026 | Moran Sean F. | Chief Financial Officer | Open-market sale | −12,000 | $10.08 | 84,694 | Form 4 |
| 7 August 2026 | Cohen Yuval | Chief Executive Officer | Open-market sale | −17,000 | $10.08 | 157,316 | Form 4 |
| 10 June 2026 | Altmeyer Anne | Director | Open-market sale | −2,412 | $7.91 | 7,579 | Form 4 |
| 10 June 2026 | Jenkins John Kenneth | Director | Open-market sale | −4,800 | $7.91 | 3,833 | Form 4 |
| 10 June 2026 | Kung Winston | Director | Open-market sale | −2,026 | $7.91 | 12,140 | Form 4 |
| 3 June 2026 | Saxena Nishant C | Chief Business Officer | Open-market purchase | +9,000 | $7.58 | 75,300 | Form 4 |
| 2 June 2026 | Saxena Nishant C | Chief Business Officer | Open-market purchase | +4,500 | $7.33 | 66,300 | Form 4 |
| 21 May 2026 | Saxena Nishant C | Chief Business Officer | Grant or award | +58,300 | — | 61,800 | Form 4 |
| 19 May 2026 | Pfeiffenberger Brent | Director | Grant or award | +7,500 | — | 7,500 | Form 4 |
| 19 May 2026 | Ben Yong | Director | Grant or award | +3,800 | — | 11,383 | Form 4 |
| 19 May 2026 | Altmeyer Anne | Director | Grant or award | +3,800 | — | 9,991 | Form 4 |
| 19 May 2026 | Jenkins John Kenneth | Director | Grant or award | +3,800 | — | 8,633 | Form 4 |
| 19 May 2026 | Jacques Rachelle Suzanne | Director | Grant or award | +3,800 | — | 11,383 | Form 4 |
| 19 May 2026 | Kung Winston | Director | Grant or award | +3,800 | — | 14,166 | Form 4 |
| 2 March 2026 | Smethurst Dominic | Chief Medical Officer | Open-market sale | −6,097 | $8.30 | 89,790 | Form 4 |
| 17 February 2026 | Hodgson Ian | Chief Operating Officer | Open-market sale | −847 | $7.38 | 51,080 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Corbus Pharmaceuticals page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.